Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Ibio Inc
IBIOiBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. The company's vaccines and therapeutics in preclinical development. Its EngageTx" technology targets bi-specific molecules and its pre-clinical data demonstrates the ability to generate multiple hits creating sequence diversity and promoting Human-Cyno cross reactivity while mitigating cytokine release. The company also has ShieldTx", a patent-pending antibody masking technology designed to enable specific targeted antibody delivery to diseased tissue without harming healthy tissue. The company was incorporated in 2008 and is headquartered in San Diego, California. Address: 11750 Sorrento Valley Road, San Diego, CA, United States, 92121
Analytics
Zielpreis von Wall Street
4.3 USDKGV
–Dividendenrendite
–Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen IBIO
Dividenden-Analyse IBIO
Dividendenwachstum über 5 Jahre
–Kontinuierliches Wachstum
–Ausschüttungsquote 5-Jahres-Durchschnitt
–Verlauf der Dividende IBIO
Bewertung der Aktie IBIO
Finanzen IBIO
Ergebnisse | 2019 | Dynamik |